Galena Biopharma’s management team brings together experienced biotech management and scientists to accelerate value for patients and shareholders.
Mark J. Ahn, Ph.D. is President & Chief Executive Officer, and Director of Galena Biopharma (Nasdaq: GALE). Dr. Ahn has served as our President and Chief Executive Officer since March 31, 2011 and as a director since 2007; and adjunct Professor, Biosciences at Creighton University. He brings more than 20 years of experience in the biopharmaceutical industry. Prior to joining Galena, starting in 2011, Dr. Ahn was Principal at Pukana Partners, Ltd., which provides strategic consulting to life science companies; and Associate Professor, Global Management at Atkinson Graduate School of Management, Willamette University. He previously served as Professor and Chair, Science & Technology Management, Victoria University at Wellington, New Zealand. Dr. Ahn was also founder, President, and Chief Executive Officer of Hana Biosciences. Prior to joining Hana, he served as Vice President, Hematology and corporate officer at Genentech, Inc., and held positions of increasing responsibility at Amgen and Bristol-Myers Squibb. Dr. Ahn also serves on public and venture capital-backed board of directors for Access Pharmaceuticals, Mesynthes and ScribesSTAT. Dr. Ahn is the author of over 50 peer reviewed journal articles and books. Dr. Ahn received a B.A. and M.B.A. from Chaminade University; and M.A. from Victoria University. He was a graduate fellow in Economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.
Dr. Hamilton has extensive academic and pharmaceutical experience in immunology, hematopoietic stem cell transplantation, and oncology. Having worked in both large pharmaceutical companies such as AstraZeneca and Wyeth, as well as biotech companies such as BioVex, Soligenix, and Onyx, he has experience with drug development across multiple therapeutic indications and platforms, including small molecules, biologics, oncolytic viruses, and vaccines. He has been a partner and Vice President of Biopharm Solutions, a private consulting firm in the life sciences industry, since 2001. Dr. Hamilton received his M.D. and Ph.D. from the University of Washington School of Medicine with extensive specialty training to include Pediatrics at the Children’s Medical Center in Dallas, Texas, Immunology at the Children’s Hospital Medical Center and Sidney Farber Cancer Center, and Allergy at the University of California-San Francisco. He has held academic appointments at the University of Washington and the University of Miami.
Dr. Schwartz joins Galena Biopharma after serving as Executive Vice President and Chief Operating Officer of RXi Pharmaceuticals. He joined RXi as part of the Apthera acquisition where he had been the President and Chief Executive Officer of Apthera, Inc. Prior to joining Apthera, Dr. Schwartz served for five years as President and CEO of Bayhill Therapeutics, a company developing an innovative DNA vaccine platform for the treatment of autoimmune diseases where he complete a successful partnership with Genentech for the development of the company’s type 1 diabetes vaccine. He had also served as President and CEO of Calyx Therapeutics, which doubled its size, nurtured a successful working relationship with the Food & Drug Administration (FDA), and completed key phase I and phase II international clinical trials of novel anti-inflammatory compounds during his tenure.
Dr. Moran has more than 25 years of pharmaceutical industry experience in research, regulatory affairs, and quality assurance in start-up and high growth companies including Sangstat, Scios, Athena, Intarcia and Hana Biosciences. She led marketing approvals for nine pharmaceutical products, including drugs, biologics, medical devices and in vitro diagnostics globally, including oncology. Dr. Moran earned an MSc in Chemical Engineering from Slovak Technical University, Bratislava, Slovakia and a Ph.D. in Organic Chemistry from the Weizmann Institute of Science, Rehovoth, Israel.
More than 12 years of experience in clinical critical care provide the backdrop for Ms. Sutton’s move into the pharmaceutical industry nearly two decades ago. Lynn began her career in the Pharmaceutical Industry as a Global Project Manager in Cardiovascular Research at Schering Plough Pharmaceuticals, running the pivotal trial for the Imdur registration study. With nearly 20 years in the industry, Lynn has worked in large pharmaceuticals, biopharmaceuticals, the CRO environment and as an independent consultant in conducting Clinical Research in roles that included, CRA Manager, Project Manager, Manager/Director of Clinical Safety & Clinical Development, Director Clinical Operations, Vice President of Clinical Drug Development. More recently, Lynn was the Vice President of Clinical Services at Allos Therapeutics prior to joining Galena in the role of Vice President of Clinical Operations. Throughout her career she has been responsible for overseeing global programs across all phases of development, focusing primarily in Oncology and orphan indications.
Christopher S. Lento joined Galena as its Vice President, Sales and Commercial Operations to launch Abstral. Mr. Lento has 20 years of experience in senior level positions managing the sales, business development and operations at major healthcare companies including Genentech BioOncology, Altos Solutions, Abraxis Bioscience (acquired by Celgene Corporation), and US Oncology Network.
Mr. Dunlap is a CPA with 15 years of experience in accounting and finance, including 11 years in public accounting at large national and regional firms with a focus on the technology and life science industries. Mr. Dunlap also served as the Director of Accounting at Vestas Wind Systems A/S, a public company that manufactures wind turbines and constructs wind parks, and in the Corporate Audit department at Nike, Inc., planning and executing operational and financial audits and leading Sarbanes Oxley implementation and maintenance teams. Mr. Dunlap holds a B.S. in Accounting from the University of Oregon, and serves as Treasurer on the Executive Committee of the Oregon Bioscience Association.
Scientific Advisory Board
Dr. Peoples graduated from West Point in 1984 and from Johns Hopkins School of Medicine in 1988. After a surgical internship at Walter Reed Army Medical Center (WRAMC), he completed his surgical training at the Brigham and Women’s Hospital in Boston, MA in 1996. During that time, Dr. Peoples also completed a research fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MD Anderson Cancer Center (MDACC) in Houston, TX in 1998. He served as the Chief, Surgical Oncology at WRAMC until 2006 when he assumed the same position at Brooke Army Medical Center in San Antonio, TX. Currently, Dr. Peoples continues in this clinical role as well as serves as the Director of the Cancer Vaccine Development Program, Deputy Director of the United States Military Cancer Institute, Professor of Surgery at the Uniformed Services University of the Health Sciences, and Adjunct Professor of Surgical Oncology at MDACC. He is the PI on numerous multi-center clinical trials of cancer vaccines being conducted nationally and internationally. He has written extensively on the immune response to cancer.
Dr. Hope S. Rugo is a Clinical Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, where she directs Breast Oncology and Clinical Trials Education and has an active clinical practice. Her research interests include novel therapies for advanced breast cancer, evaluation of circulating cells as novel markers of response and resistance to therapy, and complementary medicine and supportive care. Dr. Rugo is an investigator in the Bay Area Spore at UCSF breast cancer center, and the principal investigator of a number of clinical trials. She has published many peer-reviewed papers and has given presentations on a variety of cancer related topics. She is a member of the Alliance breast core committee and is the principal investigator of a Phase 3 CALGB therapeutic study for advanced breast cancer that has recently completed accrual. After graduating summa cum laude from Tufts University, Dr. Rugo received her M.D. from the University of Pennsylvania and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. She also completed a two-year postdoctoral fellowship in immunology at Stanford University.
Dr. Figlin is a prolific researcher known for advancing cancer therapies. His expertise has resulted in the development of novel anti-cancer drugs that have led to improved outcomes for patients. Dr. Figlin has written more than 300 peer-reviewed publications, authored several books on kidney cancer, and published more than 60 book chapters on new approaches to cancer treatment. He is a fellow of the American College of Physicians and the International Society for Biologic Therapy as well as a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Urological Association.
Dr. Gabriel N. Hortobagyi, M.D., F.A.C.P., is a Professor of Medicine and Chairman of the Department of Breast Medical Oncology and holds the Nellie B. Connally Chair in Breast Cancer Research at the University of Texas MD Anderson Cancer Center (MDACC). Dr. Hortobagyi joined MDACC as a Medical Oncology Fellow in 1974 after graduating from the Universidad National of Colombia in 1970 and completing his internal medicine residency at Case Western Reserve Hospitals in Cleveland, OH. He is an internationally recognized expert on the development of breast cancer therapeutics. He pioneered research with preoperative chemotherapy to reduce the size of large tumors and developed and conducted the definitive clinical trials with bisphosphonates in the prevention of bone-related complications in metastatic breast cancer. Dr. Hortobagyi also conducted one of the earliest randomized trials testing high-dose chemotherapy and autologous hematopoietic stem cell transplant in primary breast cancer. Since 1993, he has pioneered the development of gene therapy for breast cancer. He is Senior Editor for The Oncologist (also section editor for breast cancer) and serves as Associate Editor for Annals of Surgical Oncology, Targeted Oncology, and Clinical and Translational Oncology and as Contributing Editor for Breast Diseases. Dr. Hortobagyi serves (or has served) on more than 30 editorial boards. For the American Society of Clinical Oncology (ASCO), he has served on the Board of Directors since 2002 and was President from 2006-2007.
Board of Directors
Mr. Hillsberg has been the Chairman of our board of directors since 2007. Mr. Hillsberg has been an attorney with TroyGould PC since 1976 and is a member of the firm’s Management Committee. Mr. Hillsberg is a founder and former director of ImmunoCellular Therapeutics, Ltd., a publicly-held biopharmaceutical company formed to develop cellular therapies, including dendritic cell-based vaccines for the treatment of brain and other cancers. Mr. Hillsberg has also served as a director of Tempra Technology, Inc., a thermal research and development company, since 1997. Mr. Hillsberg served as a director and Secretary of Duska Therapeutics, Inc., a publicly-held biopharmaceutical company, and its predecessor company from 1999 until January 2006. He previously served as a director and Vice President of Medco Research, Inc., a then publicly-held pharmaceutical company. Mr. Hillsberg is a member of the Board of Governors of Cedars-Sinai Medical Center and has also previously served as a Commissioner of the Quality and Productivity Commission of the City of Los Angeles. Mr. Hillsberg holds a B.A. degree from the University of Pennsylvania and a J.D. degree from Harvard Law School.
Dr. Chin has been one of our directors since 2009. Dr. Chin is currently the Chief Executive Officer of Institute for OneWorld Health, a nonprofit pharmaceutical company developing drugs for neglected diseases in developing countries. Prior to joining iOWH, Dr. Chin served as the President and CEO of OXiGENE a NASDAQ-listed company developing vascular targeting drugs for oncology and ophthalmology. Previously, Dr. Chin served as Senior Vice President and Head of Global Development for Elan Corporation, plc from May 2005 until 2006 and served as Senior Vice President and Head of Global Medical Affairs of Elan from June 2004 until May 2005. As Senior Vice President and Head of Global Development for Elan Corporation, Dr. Chin had worldwide responsibility for Clinical Development, Regulatory, Biostatistics, CMC, QA/Compliance, Safety and Medical Affairs. Prior to June 2004, Dr. Chin served in various clinical and scientific roles of increasing responsibility for Genentech, Inc. between March 1999 and June 2004, and ultimately served as the company’s Group Director and Head of Clinical Research, Biotherapeutics Unit. While at Genentech, Dr. Chin oversaw approximately 50% of its Phase I through Phase IV clinical trials. He played leadership roles on multiple projects, including Genentech’s anti-VEGF antibody, Lucentis, and served as Team Leader for Avastin® Non-Oncology Teams. Dr. Chin began his career in pharmaceuticals in July 1997 at Procter and Gamble Pharmaceuticals where he served as Associate Medical Director. Dr. Chin holds a Medical Degree from Harvard Medical School. He received a Masters Degree and Bachelor of Arts degree in Law with honors from Oxford University, England under a Rhodes Scholarship. He graduated with a Bachelor of Arts in Biology, magna cum laude, from Harvard University. Dr. Chin is a Diplomate, American Board of Internal Medicine and is licensed to practice medicine in California. Dr. Chin currently serves on the Board of Directors of Genmedica, located in Barcelona, Spain.
Mr. Galliker has been one of our directors since 2007. Mr. Galliker served as the Executive Vice President, Finance and Administration, and Chief Financial Officer of Dyax Corp., a biopharmaceutical company focused on advancing novel biotherapeutics for unmet medical needs, from 1999 until his retirement in July 2008. From 1996 to 1999, Mr. Galliker was the Chief Financial Officer of Excel Switching Corporation, a developer and manufacturer of open switching platforms for telecommunications networks, and was Excel’s Vice President, Finance and Administration from 1997 to 1999. From 1992 to 1996, Mr. Galliker was employed by Ultracision, Inc., a developer and manufacturer of ultrasonically powered surgical instruments, where he served as Chief Financial Officer and Vice President of Finance until 1995, when he became Ultracision’s Chief Operating Officer. Mr. Galliker is also a director of Osteotech, Inc., a medical device company. Mr. Galliker is a Certified Public Accountant and received a B.S. from Georgetown University and an M.B.A. from the University of Chicago.
Mr. Kriegsman has been one of our directors since 2006. Mr. Kriegsman has been a director and the President and Chief Executive Officer of CytRx Corporation since July 2002. He previously served as Director and Chairman of Global Genomics from June 2000 until July 2002. Mr. Kriegsman is the Chairman of the Board and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. Mr. Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman has also received a certificate for successful completion of the directors’ College 2009 Executive Program at the Stanford Law School. Mr. Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. From June 2003 until February 2008, he served as a Director, and he is the former Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been active in various organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, and the Palisades-Malibu YMCA.
Dr. Nisi has been one of our directors since 2009. Dr. Nisi has held various positions at New York Westchester Square Medical Center. In addition to having been on the Active Staff in Internal Medicine/Cardiology since 1963, Dr. Nisi is also Director of Medicine since 1975, Chief of Cardiology since 1975, Chairman of Medical Critical Care Unit since 1975, President of the Medical Board from 1977 to 1978, Chairman of the Board of Trustees since 1983 and from 1976 to 1978, Chairman of the ER Committee since 1984, and Vice-President of Medical Affairs since 1993. Dr. Nisi is a founder and the Chairman of the Board of Trustees of Medco Research, a publically held pharmaceutical company that was acquired by King Pharmaceuticals after successfully developing and marketing Adenocard, a drug that is used in most ambulances for approximately six years. Dr. Nisi has also served as an Attending Physician at New York Hospital, a Clinical Assistant Professor of Medicine at Cornell University Medical College and an Assistant Dean at Weill Medical College of Cornell University. Dr. Nisi has also served as a director of Tempra Technology, Inc., a thermal research and development company, since 1997 and on the boards of Touchtone HMO and New York Presbyterian Hospital. Dr. Nisi holds a B.S. degree from Fordham University and a Doctor of Medicine degree from the University of Rome Medical School in Rome, Italy and is a fellow in the American College of Cardiology.
William L. Ashton joined the Company’s Board of Directors in May 2013. Mr. Ashton is a senior executive with more than twenty-eight years of experience in biotechnology and pharmaceutical leadership and management. Most recently, at Amgen, Inc., he served as Vice President of corporate and government affairs and Vice President of sales, and was directly responsible for product launches, as well as interaction with key government agencies including the Centers for Medicare and Medicaid Services. After retiring from Amgen, Mr. Ashton joined the University of the Sciences in Philadelphia where he currently serves as Associate Provost and Senior Vice President of Strategic Business Development, Founding Dean, Mayes College of Healthcare Business and Policy, and Assistant Professor of Pharmaceutical Business.
Mark J. Ahn, Ph.D. is President & Chief Executive Officer, and Director of Galena Biopharma (Nasdaq: GALE). Prior to Galena Biopharma, Dr. Ahn was Principal at Pukana Partners, Ltd. that provides strategic consulting to life science companies; and Associate Professor, Global Management at Atkinson Graduate School of Management, Willamette University. He previously served as Chair, Science & Technology Management, Victoria University at Wellington, New Zealand. Dr. Ahn was also founder, President, and Chief Executive Officer of Hana Biosciences. Prior to Hana, he served as Vice President, Hematology and corporate officer at Genentech, Inc., as well as held positions of increasing responsibility at Amgen and Bristol-Myers Squibb Company; and served in the US Army. Dr. Ahn also serves on public and venture capital-backed Board of Directors for Access Pharmaceuticals, Mesynthes and Scribes STAT. Dr. Ahn is the author of over 50 peer reviewed journal articles and books including Making the Case for Biotechnology (Logos Press).